Clinical Trial: Adaptive Dosing of Immune Checkpoint Inhibitors for Hepatocellular Carcinoma

U.S., July 9 -- ClinicalTrials.gov registry received information related to the study (NCT07689175) titled 'Adaptive Dosing of Immune Checkpoint Inhibitors for Hepatocellular Carcinoma' on June 30.

Brief Summary: The goal of this clinical trial is to learn if immunotherapy including nivolumab plus ipilimumab is effective and safe in treating hepatocellular carcinoma.

Study Start Date: Oct. 31, 2026

Study Type: INTERVENTIONAL

Condition: Hepatocellular Carcinoma (HCC)

Intervention: DRUG: Nivolumab

Nivolumab 1 mg/kg every 3 weeks for a maximum of 4 doses as part of combination therapy; then 240 mg every 2 weeks or 480 mg every 4 weeks as single agent.

DRUG: Ipilimumab (3 mg/kg)

ipilimumab 3 mg/kg for a maximum of 4 doses as part of c...